# POINT Biopharma (stock symbol: PNT) Logo in transparent PNG and SVG formats

## POINT Biopharma Logo large

### POINT Biopharma Logo large Download PNG (25.84 KB)

![POINT Biopharma Logo large Download PNG (25.84 KB)](/img/orig/PNT_BIG-3b6dab4e.png)

### POINT Biopharma Logo large Download SVG (7.58 KB)

![POINT Biopharma Logo large Download SVG (7.58 KB)](/img/orig/PNT_BIG-ba1fd9bd.svg)

## POINT Biopharma Logo icon format

### POINT Biopharma Logo icon format Download PNG (18.69 KB)

![POINT Biopharma Logo icon format Download PNG (18.69 KB)](/img/orig/PNT-713e2679.png)

### POINT Biopharma Logo icon format Download SVG (2.25 KB)

![POINT Biopharma Logo icon format Download SVG (2.25 KB)](/img/orig/PNT-fac5a801.svg)

## POINT Biopharma Logo large for dark backgrounds

### POINT Biopharma Logo large for dark backgrounds Download PNG (25.84 KB)

![POINT Biopharma Logo large for dark backgrounds Download PNG (25.84 KB)](/img/orig/PNT_BIG.D-a9d23e9f.png)

### POINT Biopharma Logo large for dark backgrounds Download SVG (7.58 KB)

![POINT Biopharma Logo large for dark backgrounds Download SVG (7.58 KB)](/img/orig/PNT_BIG.D-5f5e8f52.svg)

## POINT Biopharma Logo icon format for dark backgrounds

### POINT Biopharma Logo icon format for dark backgrounds Download PNG (18.69 KB)

![POINT Biopharma Logo icon format for dark backgrounds Download PNG (18.69 KB)](/img/orig/PNT.D-ef6ac80d.png)

### POINT Biopharma Logo icon format for dark backgrounds Download SVG (2.25 KB)

![POINT Biopharma Logo icon format for dark backgrounds Download SVG (2.25 KB)](/img/orig/PNT.D-1d0a1b87.svg)

## About POINT Biopharma

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

1. Website domain: pointbiopharma.com
2. Employees: 72
3. Marketcap: $0.81 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
